SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff has centered on concerns about its debt burden, distressed bond trading, and ability to finance its AI data-center expansion. Goldman Sachs Buy upgrade prompted hopes for a rebound, but traders debated whether the move could overcome financing risks, with bearish concerns about dilution or default competing with dip-buying and oversold-bounce calls.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention for its steep slide to fresh lows, as traders question the companys business prospects and debate whether Trumps political standing and the approaching midterms could further weaken its appeal. Sentiment is heavily bearish, though a few traders see the decline as a buying opportunity or cite possible merger and fusion developments.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs continued slide to fresh lows is being tied to soft residential roofing demand, housing-sector pressure and analyst target cuts, with traders also pointing to high rates and suspected dilution. Many are frustrated by the decline and managements limited communication, while some long-term holders remain optimistic about the building-products roll-up and future integration gains.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep selloff, with traders frequently citing insider selling and IPO lockup share releases as sources of supply pressure, alongside valuation and growth concerns. Bulls see an oversold AI-inference opportunity, while bears remain concerned about further selling, the companys ability to scale, and its reliance on OpenAI.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is drawing attention for its steep selloff and persistent underperformance, with traders citing weakness in crypto and AI infrastructure alongside concern about its CoreWeave tenancy and delays in securing additional data-center tenants. Many blame management and a lack of communication, while some remain hopeful that Helios revenue or earnings will demonstrate the businesss potential.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood shares are under pressure amid a sustained selloff, with analyst caution and valuation concerns ahead of earnings adding to traders worries; some also point to broader market weakness and crypto declines. The bearish mood and speculation about insider selling or unusual activity contrast with dip-buyers who see the decline as an opportunity.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDAs acceptance of CorMedixs REZZAYO supplemental application for priority review in invasive fungal-disease prevention is drawing attention, with traders focused on the potential label expansion and upcoming regulatory decision. Enthusiasm is tempered by frustration that the news has barely moved the share price and broader concerns about DefenCaths reimbursement and competition; acceptance does not guarantee approval.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after its Phase 3 APOLLO trial of bitopertin met both primary and all secondary endpoints in erythropoietic protoporphyria, strengthening the case for an FDA resubmission after an earlier rejection. Traders are weighing the positive results and potential short-covering against profit-taking, heavy selling, and the remaining regulatory uncertainty.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoin and broader crypto-market volatility are driving attention, with traders repeatedly criticizing COIN for falling sharply on weak crypto days while lagging during rebounds. Sentiment is split between frustration over its underperformance and hopes for a recovery, with upcoming quarterly results adding to the debate.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs better-than-guided third-quarter results and upbeat outlook for higher EBITDA have driven a sharp rally, with traders also discussing potential short covering. Bulls see improving steel pricing and contracts supporting a recovery, while skeptics question whether the outlook can overcome the companys debt and past volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.

All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy

Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging  Acumen Pharmaceuticals (ABOS) This Year?

Acumen Pharmaceuticals (ABOS) Expected to Announce Quarterly Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-acumen-pharmaceuticals-inc-stock...

Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Increases By 46.4%

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totaling 1,545,029 shares, an increase of 46.4% from the March 31st total of 1,055,415 shares. Approximately 2.4% of the...

Acumen Pharmaceuticals (NASDAQ:ABOS) Trading 0.7% Higher   - Still a Buy?

Acumen Pharmaceuticals (NASDAQ:ABOS) Shares Up 0.7% - Here's Why...

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.

Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday...

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Newton, MA.

Acumen Pharmaceuticals Inc

Bullish Sentiment

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$1.78
Prev Close	$1.69
Open	$1.68
Dividend Yield	0.00%
50-Day Moving Average	$2.56
Beta	1.61
Avg. Volume	504,073.96
PE Ratio	-1.04

52-Week High	$3.60
52-Week Low	$1.50
Market Capitalization	$122.22M
EPS (Annual)	-$2.00
Price to Book	2.13
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABOS Fundamentals